XRTX
XORTX Therapeutics Inc
NASDAQ: XRTX · HEALTHCARE · BIOTECHNOLOGY
$1.70
-0.58% today
Updated 2026-09-29
Market cap
$3.09M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.58
Dividend yield
—
52W range
$2 – $7
Volume
0.3M
WallStSmart proprietary scores
24
out of 100
Grade: F
Strong Sell
Investment rating
3.7
Growth
D4.8
Quality
C3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
-14.2
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →262 stocks currently score above 75
Price targets
Analyst target
$14.04
+725.88%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -14.19 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-6.34M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-10.45M | $-2.16M | $-3.15M | $-2.66M | $-1.69M |
| EPS | — | — | — | — | $-2.58 |
| Free cash flow | $-8.21M | $-6.63M | $-3.72M | $-2.82M | $-6.34M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
XORTX Therapeutics Inc trades at $1.70. Our Smart Value Score of 24/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -14.19, it sits in the distress.
Frequently asked questions
What is XORTX Therapeutics Inc's stock price?
XORTX Therapeutics Inc (XRTX) trades at $1.70.
Is XORTX Therapeutics Inc overvalued?
XORTX Therapeutics Inc carries a Smart Value Score of 24/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of XORTX Therapeutics Inc (XRTX)?
The 12-month analyst consensus target is $14.04, about 725.9% above the current $1.70. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
XORTX Therapeutics Inc's Altman Z-Score is -14.19, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-213.89%
Beta0.44
50D MA$2.09
200D MA$2.34
Shares out0.00B
Float0.00B
Short ratio—
Avg volume0.3M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—